Catalyst Biosciences, Inc. has entered into an exclusive worldwide research and license agreement with Centocor R&D, Inc. Centocor will support Catalyst’s discovery research and preclinical development of Alterase drug candidates against two targets. The first target is in inflammatory disease, with an option to expand the agreement to include a third target. Alterase therapeutics are next-generation protease biologics engineered to catalytically split and inactivate disease-causing pr...